➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
AstraZeneca
McKinsey
Colorcon
Moodys

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

LAMISIL AT Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Lamisil At patents expire, and what generic alternatives are available?

Lamisil At is a drug marketed by Glaxosmithkline Cons and is included in two NDAs.

The generic ingredient in LAMISIL AT is terbinafine hydrochloride. There are twenty-seven drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the terbinafine hydrochloride profile page.

Drug patent expirations by year for LAMISIL AT
Drug Prices for LAMISIL AT

See drug prices for LAMISIL AT

Recent Clinical Trials for LAMISIL AT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hamilton Academic Health Sciences OrganizationPhase 2
Hamilton Health Sciences CorporationPhase 2
GlaxoSmithKlinePhase 1

See all LAMISIL AT clinical trials

US Patents and Regulatory Information for LAMISIL AT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 OTC Yes Yes   Start Trial   Start Trial   Start Trial
Glaxosmithkline Cons LAMISIL AT terbinafine hydrochloride SOLUTION;TOPICAL 021124-001 Mar 17, 2000 OTC Yes Yes   Start Trial   Start Trial   Start Trial
Glaxosmithkline Cons LAMISIL AT terbinafine hydrochloride SPRAY;TOPICAL 021124-002 Mar 17, 2000 OTC Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LAMISIL AT

Supplementary Protection Certificates for LAMISIL AT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0024587 SPC/GB93/096 United Kingdom   Start Trial SPC/GB93/096, EXPIRES: 20050805
0024587 93C0136 Belgium   Start Trial PRODUCT NAME: TERBINAFINE (250 MG) SOUS FORME DE CHLORHYDRATE (281,25 MG); NAT. REG.: 616 S 201 F3 19911031; FIRST REG.: GB PL 0101/0304 19901003
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
AstraZeneca
McKinsey
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.